Replies to post #113172 on Biotech Values

[marthambles]

Dewophile

I agree with your four reasons. The fifth and perhaps most important reason is the possiblility of FDA action on M-copaxone in the near term.

[Cactus Quave]

i think the likelihood of teva approval is higher

Higher than when? Up until today, we have been led to believe by Teva that approval was due by the end of this month, but of course we were told earlier that approval would likely come by then end of last year, and before that...

As Dew has pointed out, Teva does not even say in today's PR that they expect approval. As Dew and others have pointed out, a Minor Deficiency letter does not mean that the information is easy to provide or that a drug is any closer to approval. Teva does not even say in their PR that they are confident that they can respond to the "short list of questions" to the satisfaction of the FDA.

Given Teva's track record of misleading PR regarding their generic Lovenox ANDA, why should anyone read today's PR as being anything different?

[ghmm]

I agree with your train of thought but did more then hold my shares :-)... After running I came back and made a couple purchases. I agree with your earlier post on valuation and though I probably think a buyout is less likely then you I think the "value" in the company is significantly higher and think their FOB program is worth a fair amount and is increasing in value... Plus I heard Wheeler's last presentation again (while Running) and think a Teva approval could come later rather then sooner and the market has priced in as very soon.